• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Amicus Therapeutics Inc.

    11/14/24 11:37:23 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email
    SC 13G 1 tm2428293d19_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. )*

     

     

    Amicus Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    03152W109
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP: 03152W109 Page 2

     

     

    1.

     

    NAME OF REPORTING PERSONS

     

    William Blair Investment Management, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

     

    14,002,505

     

    6.

     

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    15,582,962

     

    8.

     

     

    SHARED DISPOSITIVE POWER

     

    0

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    15,582,962

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.3%

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

           

    3

     

     

     

    CUSIP: 03152W109 Page 3

     

    Item 1(a). Name of Issuer:
      Amicus Therapeutics, Inc.
    Item 1(b). Address of Issuer’s Principal Executive Offices:
      47 Hulfish Street, Princeton, New Jersey, 08542
       
    Item 2(a). Name of Person Filing:
      William Blair Investment Management, LLC
    Item 2(b). Address of Principal Business Office or, if none, Residence:
      150 North Riverside Plaza, Chicago, IL 60606
    Item 2(c). Citizenship:
      Delaware
    Item 2(d). Title of Class of Securities:
      Common Stock
    Item 2(e). CUSIP Number:
      03152W109
    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

     

    CUSIP: 03152W109 Page 4

     

    Item 4. Ownership:
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 15,582,962
      (b) Percent of class: 5.3%
      (c) Number of shares as to which the person has:
        (i) Sole power to vote or to direct the vote: 14,002,505
        (ii) Shared power to vote or to direct the vote: 0
        (iii) Sole power to dispose or to direct the disposition of: 15,582,962
        (iv) Shared power to dispose or to direct the disposition of: 0
    Item 5. Ownership of Five Percent or Less of a Class:
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
      N/A
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
      N/A
    Item 8. Identification and Classification of Members of the Group:
      N/A
    Item 9. Notice of Dissolution of Group:
      N/A
    Item 10. Certifications:
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP: 03152W109 Page 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Date:  November 14, 2024
         
      By:  /s/ Stephanie Braming
         
      Name:  Stephanie Braming
         
      Title:  Partner, Global Head of Investment Management
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations

    (see 18 U.S.C. 1001).

     

     

     

     

     

    Get the next $FOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    2/24/2022$16.00 → $14.00Outperform
    SVB Leerink
    More analyst ratings

    $FOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:00:58 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Amicus Therapeutics Inc.

      SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 11:37:23 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

      SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      11/14/24 9:31:54 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

      PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve. In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. In PROPEL, 77% of patients (n=95) received enzyme replacement therapy (ERT) with alglucosidase alfa before study entry, with a median ERT duration of 7.4 years. In this new

      6/3/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

      PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ETGoldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient

      5/30/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

      PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. P.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordi

      5/7/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

      SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      5/15/25 9:30:38 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amicus Therapeutics Inc.

      10-Q - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      5/1/25 4:02:46 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      5/1/25 7:00:45 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Leadership Updates

    Live Leadership Updates

    See more

    $FOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

      Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

      8/21/23 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

      PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

      6/14/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

      Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

      5/6/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Amicus Therapeutics from Overweight to Equal-Weight and set a new price target of $12.00 from $17.00 previously

      12/13/24 7:53:22 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Amicus Therapeutics with a new price target

      Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00

      9/6/24 7:39:36 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amicus Therapeutics with a new price target

      Wells Fargo initiated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $18.00

      5/30/24 7:51:51 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Financials

    Live finance-specific insights

    See more
    • Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

      1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and c

      5/1/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

      PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com

      4/21/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

      2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2024. "We closed 2024 beating expectations with exceptional revenue growth of 33 percent. With our portfolio and global rare disease capabilities, we have a clear path to deliver cont

      2/19/25 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Campbell Bradley L covered exercise/tax liability with 13,375 shares, decreasing direct ownership by 1% to 1,137,282 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      3/18/25 5:56:44 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Campbell Bradley L exercised 400 shares at a strike of $9.03 and sold $4,000 worth of shares (400 units at $10.00) (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      2/21/25 7:27:08 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Accounting Officer Prout Samantha was granted 27,416 shares and covered exercise/tax liability with 13,500 shares, increasing direct ownership by 15% to 109,441 units (SEC Form 4)

      4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)

      2/13/25 5:22:50 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care